Article | November 30, 2020

Considerations In Combination Product Risk Management

By Susan Neadle, Johnson & Johnson, Inc.; Jennifer L. Riter, West Pharmaceutical Services, Inc.; T. Page McAndrew, West Pharmaceutical Services, Inc.

WestSelfDose

Drug-device combination products (CP’s) are an ever-increasing presence in the pharmaceutical landscape. Benefits include more convenience for patients, lower costs from fewer/eliminated hospital/clinic visits, fewer steps in usage as drug product may not need to be withdrawn from a vial, better safety with automatic needle retraction, and better compliance through connectivity such as smartphone apps. As with any pharmaceutical product, commercial offering requires demonstration of performance and compliance with applicable regulations.

This article is a review of select aspects of the webinar Creating an Effective Combination Products Risk Management Program: Special Considerations for Control and Analytical Testing Strategies Development.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Med Device Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

West Pharmaceutical Services, Inc.